{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T19:59:31Z","timestamp":1785614371315,"version":"3.56.0"},"reference-count":29,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Heterogeneity exists among patients with myositis who have antinuclear matrix protein 2 (anti-NXP2) antibodies, although they usually present with severe muscle weakness. This study aimed to investigate the differences in phenotypes and prognoses among adult patients with myositis who have anti-NXP2 antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adult patients with myositis who have anti-NXP2 antibodies were enrolled from January 2010 to December 2019. Their clinical features and laboratory data were recorded retrospectively. We followed up on their survival status until June 30, 2020. A hierarchical cluster analysis, Kaplan-Meier curves, and classification and regression trees were used to analyze the data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 70 adult patients with myositis who have anti-NXP2 antibodies were enrolled. All patients experienced muscle weakness. A total of 11 patients did not present with rashes during disease progression, and 43 patients developed dysphagia. In total, 21 patients had interstitial lung disease (ILD), whereas no patients had rapidly progressive ILD. Hierarchical cluster analysis identified 2 clusters. Patients in cluster 1 were younger at disease onset, had a higher incidence of subcutaneous calcification, and had a lower incidence of V sign and shawl sign. Patients in cluster 2 had a higher frequency of ILD, accompanied by lower levels of lymphocytes and higher levels of serum ferritin. Moreover, patients in cluster 2 had worse prognoses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients with myositis who have anti-NXP2 antibodies may present with different phenotypes that are characterized by unique features and prognoses.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.211234","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T12:20:59Z","timestamp":1655295659000},"page":"922-928","source":"Crossref","is-referenced-by-count":12,"title":["Clinical Heterogeneity of Patients With Antinuclear Matrix Protein 2 Antibody\u2013Positive Myositis: A Retrospective Cohort Study in China"],"prefix":"10.3899","volume":"49","author":[{"given":"Shanshan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linrong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5425-6157","authenticated-orcid":false,"given":"Xiaoming","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"2022072810450892000_49.8.922.1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3389\/fneur.2019.00438","article-title":"Disease specific autoantibodies in idiopathic inflammatory myopathies","volume":"10","author":"Stuhlm\u00fcller","year":"2019","journal-title":"Front Neurol"},{"key":"2022072810450892000_49.8.922.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2018.12.040"},{"key":"2022072810450892000_49.8.922.3","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s10067-019-04503-7","article-title":"The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies","volume":"38","author":"Li","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2022072810450892000_49.8.922.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2004.02.006"},{"key":"2022072810450892000_49.8.922.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.10.005"},{"key":"2022072810450892000_49.8.922.6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2022072810450892000_49.8.922.7","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/acr.23188","article-title":"Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients","volume":"69","author":"Albayda","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2022072810450892000_49.8.922.8","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8510-y"},{"key":"2022072810450892000_49.8.922.9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaneurol.2020.0673","article-title":"Association of dermatomyositis sine dermatitis and with anti-nuclear matrix protein 2 autoantibodies","volume":"77","author":"Inoue","year":"2020","journal-title":"JAMA Neurol"},{"key":"2022072810450892000_49.8.922.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200697"},{"key":"2022072810450892000_49.8.922.11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","article-title":"Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study","volume":"19","author":"Yang","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2022072810450892000_49.8.922.12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/BOR.0000000000000641","article-title":"The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome","volume":"31","author":"Lu","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"2022072810450892000_49.8.922.13","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.chest.2020.04.057","article-title":"Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model","volume":"158","author":"Lian","year":"2020","journal-title":"Chest"},{"key":"2022072810450892000_49.8.922.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2014.12.001"},{"key":"2022072810450892000_49.8.922.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.04.001"},{"key":"2022072810450892000_49.8.922.16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/ene.14097","article-title":"Perimysial microarteriopathy in dermatomyositis with anti-nuclear matrix protein-2 antibodies","volume":"27","author":"Liu","year":"2020","journal-title":"Eur J Neurol"},{"key":"2022072810450892000_49.8.922.17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11926-018-0798-1","article-title":"Anti-MDA5 antibody spectrum in Western world","volume":"20","author":"Moghadam-Kia","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"2022072810450892000_49.8.922.18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clim.2018.11.008","article-title":"Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: a meta-analysis of 20 cohorts","volume":"198","author":"Zhong","year":"2019","journal-title":"Clin Immunol"},{"key":"2022072810450892000_49.8.922.19","doi-asserted-by":"crossref","first-page":"102533","DOI":"10.1016\/j.autrev.2020.102533","article-title":"Calcinosis biomarkers in adult and juvenile dermatomyositis","volume":"19","author":"Chung","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2022072810450892000_49.8.922.20","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s10067-018-4216-x","article-title":"Calcinosis and malignancy are rare in Chinese adult patients with myositis and nuclear matrix protein 2 antibodies identified by an unlabeled immunoprecipitation assay","volume":"37","author":"Wang","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2022072810450892000_49.8.922.21","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/17476348.2020.1767598","article-title":"Lung involvement associated with anti-NXP2 autoantibodies in inflammatory myopathies: a French monocenter series","volume":"14","author":"Bermudez","year":"2020","journal-title":"Expert Rev Respir Med"},{"key":"2022072810450892000_49.8.922.22","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/acr.23210","article-title":"Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients","volume":"69","author":"Rogers","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2022072810450892000_49.8.922.23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccm.2019.05.004","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"40","author":"Long","year":"2019","journal-title":"Clin Chest Med"},{"key":"2022072810450892000_49.8.922.24","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.rcl.2016.05.005","article-title":"Imaging of pulmonary manifestations of connective tissue diseases","volume":"54","author":"Ahuja","year":"2016","journal-title":"Radiol Clin North Am"},{"key":"2022072810450892000_49.8.922.25","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1093\/rheumatology\/keaa034","article-title":"Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis","volume":"59","author":"Zuo","year":"2020","journal-title":"Rheumatology"},{"key":"2022072810450892000_49.8.922.26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1684\/ejd.2019.3634","article-title":"Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease","volume":"29","author":"Motegi","year":"2019","journal-title":"Eur J Dermatol"},{"key":"2022072810450892000_49.8.922.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.03.007"},{"key":"2022072810450892000_49.8.922.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.38093"},{"key":"2022072810450892000_49.8.922.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2016.02.017"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.211234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T17:48:04Z","timestamp":1659030484000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.211234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,7,28]]},"published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.3899\/jrheum.211234"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.211234","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]}}}